List view / Grid view
26 April 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
14 April 2016 | By Victoria White, Digital Content Producer
The EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
7 April 2016 | By Victoria White, Digital Content Producer
Afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy...
7 April 2016 | By Victoria White
The approval includes the use of a new oral suspension formulation of Revolade designed for younger children who may not be able to swallow tablets...
6 April 2016 | By Victoria White
The EC has approved Opdivo (nivolumab) for locally advanced or metastatic NSCLC after prior chemotherapy and in advanced RCC after prior therapy...
21 March 2016 | By Victoria White
Enstilar is a topical spray foam treatment for psoriasis that is designed to provide patients with a convenient treatment option that can be easily applied...
24 February 2016 | By Victoria White
This is the first authorisation for necitumumab in Europe and follows US Food and Drug Administration (FDA) approval in November 2015...
19 February 2016 | By Victoria White
After the first year, patients with a history of heart attack can now continue to be treated with Brilique at the lower dose of 60mg twice daily...
19 February 2016 | By Victoria White
In combination with the current standard of care, Zurampic provides a dual mechanism of action to increase excretion and decrease production of uric acid...
3 February 2016 | By Victoria White
The European Commission (EC) has granted conditional marketing authorisation for AstraZeneca's Tagrisso (AZD9291, osimertinib) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
29 January 2016 | By Victoria White
The expanded label allows for the use of Daklinza (daclatasvir) in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV...
28 January 2016 | By Victoria White
The European Commission has approved two new indications for Lilly’s Cyramza (ramucirumab): one in patients with NSCLC and the other in patients with mCRC...
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
22 January 2016 | By Victoria White
The decision includes an update of the product information of all ambroxol and bromhexine containing products to include the rare risk of hypersensitivity reactions and a Precaution and Warning regarding severe cutaneous adverse reactions...
